Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many administration and emergency-use statements align with label instructions (intranasal, plunger fully in until green line not showing; additional dose after 15 minutes; oral carbohydrates after response; call emergency assistance). However, several claims add or misstate safety/handling details not supported by the provided label text (e.g., turning onto side for drowsiness/vomiting; “treat as an emergency” if no improvement; dosing conditionality vs label timing; and the absence of “do not give food/drink” guidance in the provided label).
Category Scores
Accurate Statements
Baqsimi (glucagon) is an emergency medicine used when someone has severe low blood sugar (severe hypoglycemia).
INDICATIONS AND USAGE: BAQSIMI is indicated for treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older.
Baqsimi is used when the person cannot swallow safely, is unconscious, or cannot take sugar by mouth.
DOSAGE AND ADMINISTRATION (Important Administration Instructions): Because severe hypoglycemia requires help of others to recover, instruct caregivers; administer as soon as possible when severe hypoglycemia is recognized. (The label text provided does not explicitly mention swallowing/unconsciousness/cannot take sugar by mouth, but the emergency caregiver-use framing is consistent with needing others to help recovery.)
The Baqsimi device is placed into a nostril of the person having low blood sugar.
2.1 Important Administration Instructions: Administer by inserting the tip into one nostril...
Pressing the plunger fully delivers the dose.
2.1 Important Administration Instructions: ...pressing the device plunger all the way in until the green line is no longer showing.
When administered, the medication sprays into the nose.
2.1 Important Administration Instructions: BAQSIMI is for intranasal use only; administer intranasal device... (The provided label text supports intranasal delivery though it does not explicitly use the word “sprays.”)
After Baqsimi, if the person is drowsy or vomiting, the person should be turned onto their side.
null
After the person wakes up and can swallow safely, fast-acting sugar should be given.
2.1 Important Administration Instructions: When the patient responds to treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia. (The label supports giving oral carbohydrates after response; it does not specifically say “wakes up and can swallow safely” or “fast-acting sugar.”)
If the person does not respond, emergency medical care should be sought right away.
2.1 Important Administration Instructions: Call for emergency assistance immediately after administering the dose. (The label does not condition on non-response for calling; it is immediate after dose.)
A second dose of Baqsimi may be needed depending on the situation and instructions provided with the prescription.
2.1 Important Administration Instructions: If there has been no response after 15 minutes, an additional dose may be administered while waiting for emergency assistance; 2.2: If no response after 15 minutes, additional 3 mg from a new device may be administered.
If the person is still too drowsy to swallow safely, do not give food or drink by mouth.
null
Baqsimi should be used as directed for the person in front of you.
2.1 Important Administration Instructions: Administer BAQSIMI as soon as possible when severe hypoglycemia is recognized; instruct patient/caregivers; administer according to shrink-wrapped tube label and Instructions for Use.
If Baqsimi is expired or damaged, it should be replaced.
null
Unsupported Statements
After Baqsimi, if the person is drowsy or vomiting, the person should be turned onto their side.
The provided label text does not include any instruction to position the patient (e.g., turn onto their side) based on drowsiness or vomiting.
After the person wakes up and can swallow safely, fast-acting sugar should be given.
The label provided specifies giving oral carbohydrates after the patient responds, but does not state “wakes up,” “can swallow safely,” or that the carbohydrates should be “fast-acting sugar.”
If the person does not respond, emergency medical care should be sought right away.
The label provided requires calling for emergency assistance immediately after administering the dose, not only when there is no response. The statement is partially misframed/over-conditional relative to the label timing.
A second dose of Baqsimi may be needed depending on the situation and instructions provided with the prescription.
The label provided specifies a specific decision point: if there has been no response after 15 minutes, an additional dose may be administered. The claim is less specific and could imply more flexible timing than the label text.
If the person is still too drowsy to swallow safely, do not give food or drink by mouth.
The provided label text only states to give oral carbohydrates when the patient responds; it does not provide an instruction about withholding food/drink when drowsy.
If Baqsimi is expired or damaged, it should be replaced.
The provided label text does not include expiration/damage disposal/replacement instructions.
Contradictions
Low
AI Statement
After Baqsimi, if the person is drowsy or vomiting, the person should be turned onto their side.
Label Reference
N/A (no positioning guidance provided in label text).
Important Omissions
Key contraindications: pheochromocytoma, insulinoma, and prior hypersensitivity to glucagon/excipients.
Importance:
High
Specific dose details: 3 mg as one actuation into one nostril; plunger until green line is no longer showing; additional 3 mg from a new device if no response after 15 minutes; dose does not need to be inhaled; do not reuse device/discard unused portion.
Importance:
Moderate
Requirement to call for emergency assistance immediately after administering the dose (not contingent on non-response).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Missing/omitted contraindications and some safety-critical instruction precision (e.g., explicit emergency-assistance timing, specific second-dose timing) reduce on-label fidelity. Several added or unspecific statements are unsupported by the provided label text (patient positioning; swallowing-safety conditional withholding food/drink; expiration/damage replacement).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Omission of key contraindications and lack of label-precise emergency/second-dose and oral carbohydrate instructions; multiple unsupported additions (positioning, expiration/damage guidance, swallowing/fast-acting sugar specifics).
Suggested Improvement
Revise claims to match provided label text: include contraindications (pheochromocytoma, insulinoma, prior hypersensitivity); state call for emergency assistance immediately after dosing; specify additional dose only if no response after 15 minutes from a new device; instruct giving oral carbohydrates after patient responds; remove unsupported instructions (turning onto side; withholding food/drink when drowsy; expiration/damaged replacement) unless added from label sections not provided.